XENE Stock Analysis: Buy, Sell, or Hold?
XENE - Xenon Pharmaceuticals Inc
$55.43
-0.46 (-0.81%)
▼
5d:
-1.03%
30d:
-5.87%
90d:
+33.17%
BUY
HIGH Confidence
Analysis Updated: May 13, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Accumulation
XENE is down 5.7% this week, but smart money is accumulating calls. Top strike: $57.5 2026-06-18 with 38 OI. Call ratio: 96% View Scanner →
Strength: 7.5/10
Get Alerted When XENE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: XENE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: XENE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: XENE is currently trading at $55.42, which is considered slightly low relative to its 30-day fair value range of $55.42 to $58.35.
Technical Outlook: Technically, XENE is in a strong uptrend. The price is currently testing key support at $54.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $78.98 (+41.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, XENE is in a strong uptrend. The price is currently testing key support at $54.69. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $78.98 (+41.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$55.42 -
$58.35
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 41.3% below Wall St target ($78.98)
Trading Range Analysis
30-Day Trading Range
$55.42 -
$58.35
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$3.76
(6.8%)
Support & Resistance Levels
Support Level
$54.69
Resistance Level
$58.86
Current Trend
Strong Uptrend
Technical data as of
May 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.36
Wall Street Target
$78.98
(+41.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: May 14, 2026 11:40 AM ET
Data refreshes hourly during market hours. Next update: 12:40 PM
Data refreshes hourly during market hours. Next update: 12:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XENE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Andrea Difabio
SELL
1342 shares
2026-03-13
Christopher John Kenney
SELL
1410 shares
2026-03-13
Ian Mortimer
SELL
7308 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 55 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 54 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 58 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
Advanced XENE Option Strategies
Professional options setups generated by AI based on today's XENE price and gamma walls.